Hong Kong On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech companies. Nearly 2.5 years later, 20 companies have seized the opportunity to IPO under the new Chapter 18A, raising a total of over HKD 34.92 billion (USD…
China China-born entrepreneurs are returning to their homeland to find an industry filled with incentives in place for innovation, independent of generics. Here, we highlight five unique biotechs looking to serve the unmet needs of patients with their cutting-edge technologies in cardiology, immunology and more. Adagene Adagene’s founder and CEO…
China The meteoric growth of the pharmaceutical industry in China in recent years has seen a host of top Chinese talent return home from studying and working overseas to establish their own firms. Dubbed ‘Sea Turtles’ (‘海龟’ haigui), as ‘海’ (hai) means ‘ocean’ in Chinese and ‘龟’ (gui) is a homonym…
China Dr Jinzi Jason Wu of Ascletis – a Chinese biotech success story that has developed rapidly in recent years – outlines the company’s journey from its founding in 2013 to now having two products on the market in China, having IPOed in Hong Kong and with a presence across the…
See our Cookie Privacy Policy Here
